Methods for treatment of cancer with an anti-tigit antagonist antibody
US-2024424092-A1 · Dec 26, 2024 · US
Method for predicting therapeutic effect of chemotherapy on renal cell cancer
US8992947B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8992947-B2 |
| Application number | US-201013264811-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 22, 2010 |
| Priority date | Apr 22, 2009 |
| Publication date | Mar 31, 2015 |
| Grant date | Mar 31, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention developed a novel antitumor agent for renal cell carcinoma that cannot be fully treated by the existing therapies. The present invention provides an antitumor agent comprising a combination drug of tegafur/gimeracil/oteracil potassium that ensures an excellent therapeutic effect in renal cell carcinoma patients that is superior to that of the existing therapies, by way of selecting the patients based on thymidylate synthase.
First claim
Opening claim text (preview).
The invention claimed is: 1. A therapeutic method for treating a patient for renal cell carcinoma comprising: measuring an expression level of thymidylate synthase gene in a cancer cell-containing biological sample obtained from a renal cell carcinoma patient; and administering a combination drug comprising tegafur/gimeracil/oteracil potassium to the patient when the patient has an expression level of thymidylate synthase gene that is equal to or less than a predetermined cut-of…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Human Necessities · mapped topic
Physics · mapped topic
- A61K31/513Primary
Human Necessities · mapped topic
Physics · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8992947B2 cover?
- The present invention developed a novel antitumor agent for renal cell carcinoma that cannot be fully treated by the existing therapies. The present invention provides an antitumor agent comprising a combination drug of tegafur/gimeracil/oteracil potassium that ensures an excellent therapeutic effect in renal cell carcinoma patients that is superior to that of the existing therapies, by way of …
- Who is the assignee on this patent?
- Akaza Hideyuki, Naito Seiji, Oka Toshinori, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/513. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 31 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).